News

NICE faces legal challenge over restriction on dementia drugs

BMJ 2006; 333 doi: 10.1136/bmj.39041.497315.DB (Published 23 November 2006)
Cite this as: BMJ 2006;333:1085.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Clare Dyer, legal correspondent
  1. 1BMJ

    The National Institute for Health and Clinical Excellence (NICE), the body that decides what treatments are supplied on the NHS in England and Wales, is facing a High Court challenge to its decision to restrict the use of drugs for Alzheimer's disease.

    NICE rejected an appeal by drug companies in October over its guidance stating that patients with early or late stage Alzheimer's disease should not have access to donepezil (Aricept), galantamine (Reminyl), or rivastigmine (Exelon) (BMJ 2006;333:165).

    The US drug company Pfizer and a Japanese biotechnology company, Eisai, …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular